Israel Englander Galera Therapeutics, Inc. Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.14 - $0.27 $10,728 - $20,690	76,630 New	76,630 $10,000
Q2 2023 Aug 14, 2023	BUY	$2.5 - $3.42 $314,100 - $429,688	125,640 New	125,640 $391,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $47,183 - $90,941	-38,051 Reduced 67.25%	18,530 $24,000
Q1 2022 May 16, 2022	SELL	$2.01 - $4.19 $196,692 - $410,020	-97,857 Reduced 63.36%	56,581 $135,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $148,729 - $969,670	117,110 Added 313.73%	154,438 $709,000
Q3 2021 Nov 15, 2021	SELL	$7.04 - $10.49 $571,788 - $851,997	-81,220 Reduced 68.51%	37,328 $302,000
Q2 2021 Aug 16, 2021	BUY	$6.08 - $10.44 $720,771 - $1.24 Million	118,548 New	118,548 $1.17 Million
Q1 2021 May 17, 2021	SELL	$8.35 - $12.39 $335,661 - $498,065	-40,199 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$8.02 - $12.81 $98,782 - $157,780	12,317 Added 44.18%	40,199 $411,000
Q3 2020 Nov 16, 2020	BUY	$6.96 - $9.12 $194,058 - $254,283	27,882 New	27,882 $252,000
Q1 2020 May 14, 2020	SELL	$5.89 - $17.67 $297,280 - $891,840	-50,472 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$9.13 - $13.9 $460,809 - $701,560	50,472 New	50,472 $664,000

909K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.07M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.